{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["atezolizumab","enzalutamide"]],"indication":"metastatic castration-resistant prostate cancer","name":"IMbassador250","nct_id":"NCT03016312","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imbassador250-nct03016312. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMbassador250","arms":[{"description":"Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).","label":"Atezolizumab + Enzalutamide","type":"EXPERIMENTAL"},{"description":"Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).","label":"Enzalutamide","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2022-12-20","type":"ACTUAL"},"conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":{"count":759,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq®"],"type":"DRUG"},{"name":"Enzalutamide","otherNames":["Xtandi®"],"type":"DRUG"}],"last_update":"2024-08-09","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2019-06-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Baseline until death from any cause (up to approximately 42 months)"}],"references":[{"citation":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL Jr, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6. Epub 2022 Jan 10.","pmid":"35013615","type":"DERIVED"}],"start_date":{"date":"2017-01-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen","url":"https://clinicaltrials.gov/study/NCT03016312"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imbassador250-nct03016312"}